FeelGood vs Hers: Which GLP-1 Provider Is Better?

By Iacob Pastina, Independent Researcher

49 providers verified independently·Independent researchHow we rank →

Hers beats FeelGood overall, scoring 7.3/10 vs 7/10. FeelGood is more affordable at $149/mo vs $199/mo. Choose FeelGood for budget-conscious cash-pay patients who want low-cost compoun. Choose Hers for women who want brand-name wegovy (injection or pill) at $149.

A side-by-side comparison of FeelGood and Hers covering pricing, scores, medication types, insurance, and more to help you decide.

FeelGood

#48 of 49
7/10

Telehealth platform offering compounded semaglutide as both a weekly injection ($149/mo starting) and a daily oral tablet ($249/mo starting), plus a premium brand-name 'original' semaglutide injection option ($1,999/mo). Cash-pay only, no insurance billing, HSA/FSA eligible. LegitScript-approved. FeelGood does not publicly disclose which states it serves, its compounding pharmacy, or its medical leadership.

Visit FeelGood
Higher Rated

Hers

#35 of 49
7.3/10

The women's health arm of Hims & Hers Health (NYSE: HIMS). In 2026 Hers signed a direct Novo Nordisk partnership adding FDA-approved Wegovy (pen and pill) at $149/mo and Zepbound via the Lilly partnership — alongside their existing compounded semaglutide and new compounded tirzepatide programs.

Visit Hers
FeatureFeelGoodHers
Our Score7/107.3/10
Starting Price$149/mo$199/mo
Medication TypeBothBoth
Insurance AcceptedNoNo
Best ForBudget-conscious cash-pay patients who want low-cost compounded semaglutide — injection or oral tablet — with free shipping, no membership fees, and a money-back weight-loss guaranteeWomen who want brand-name Wegovy (injection or pill) at $149/mo via the 2026 Novo Nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand
Ranking#48#35

Pros & Cons Compared

FeelGood

Pros

  • +Compounded semaglutide injection from $149/mo with free shipping and no separate membership or consultation fee
  • +Offers an oral compounded semaglutide tablet ($249/mo) for needle-averse patients — a non-injectable route only a handful of platforms provide
  • +LegitScript-approved — independent certification that the telehealth/pharmacy operation meets legal and safety standards, which many budget compounded shops lack
  • +Money-back weight-loss guarantee plus unlimited 24/7 messaging and appointments included

Cons

  • Does NOT publicly disclose which US states it serves — you can't confirm availability in your state before starting an intake
  • $149 is a 'starting' price (dose-escalating), not flat across all doses — your cost can rise as your dose titrates up, and FeelGood doesn't publish the full dose-by-dose schedule
  • Brand-name 'original' semaglutide injection at $1,999/mo is far above market — NovoCare direct Wegovy is $349/mo and Hers offers Wegovy at $149/mo via the 2026 Novo Nordisk partnership. Never buy brand-name through FeelGood
  • No named medical director, prescribing physicians, compounding pharmacy, founding year, or headquarters disclosed on the site — thin corporate and clinical transparency
  • Self-reported '4.8/5' rating is not tied to a named third-party platform (no linked Trustpilot/BBB), so it can't be independently verified; the advertised '15–20% weight loss' figures are FeelGood's marketing, not FDA-reviewed efficacy data
  • Compounded GLP-1s are not FDA-approved (none are) — and FeelGood offers compounded semaglutide only, no tirzepatide

Hers

Pros

  • +2026 Novo Nordisk partnership — FDA-approved Wegovy pen and Wegovy oral pill from $149/mo, one of the lowest brand-name GLP-1 prices on the market
  • +Zepbound access via the Lilly/Hims-Hers partnership announced 2026
  • +Publicly traded company (NYSE: HIMS) with strong financial backing and regulatory compliance
  • +Broader women's health platform — integrates weight loss with hormonal, skin, and wellness services

Cons

  • Membership + medication are billed separately ($39 first month / $149 ongoing membership) — watch the all-in math
  • Generic support experience — large patient volume means less personalized attention
  • Compounded pricing starts at $199/mo but stepped pricing applies at higher doses
  • Zepbound access priced at ~$1,899/mo (brand cash) via the Lilly partnership — read as access, not value

Our Verdict

Hers edges out FeelGood with a score of 7.3/10 vs 7/10. If budget is your priority, FeelGood starts at $149/mo compared to Hers's $199/mo. Choose FeelGood if you want: budget-conscious cash-pay patients who want low-cost compounded semaglutide — injection or oral tablet — with free shipping, no membership fees, and a money-back weight-loss guarantee. Choose Hers if you want: women who want brand-name wegovy (injection or pill) at $149/mo via the 2026 novo nordisk partnership, or a compounded semaglutide option from a publicly traded telehealth brand.

Still undecided? Editor's #1 Overall Pick

Embody

$299/mo · 7.3/10 · Compounded

If neither FeelGood nor Hers feels like the right fit, our overall #1 pick across all 49 GLP-1 telehealth providers is Embody — strongest balance of clinical oversight, transparent pricing, and verified availability.

Try FeelGood

Starting at $149/mo

Visit FeelGood

Try Hers

Starting at $199/mo

Visit Hers

Related comparisons

Other matchups readers comparing FeelGood or Hers tend to look at next.

Top Picks

Four programs our readers click through most.

Embody

7.3/10
$299/mo·Compounded

Gala

7.2/10
$149/mo·Brand & Compounded

Sesame Care

7.9/10
$99/mo·Brand & Compounded

Affiliate links — we earn a commission at no extra cost to you. Selection reflects what readers convert through, not editorial endorsement. Full ranking + methodology at glp1picks.com.